Representative before the EPO

Company dna cytos biotechnology ag
no operation time available
1 office
active in Legal Services

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 12 EP applications Yixin Pfister-Fu has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 14, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13701194

NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR

IPC classification:
A61K 31/407, C07D 487/04, A61P 5/38
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13712589

FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS

IPC classification:
A61K 31/506, A61P 19/08
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13718671

TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE

IPC classification:
A61K 45/06, A61K 31/53, A61K 31/506, A61K 31/5025
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13720275

COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS

IPC classification:
A61K 38/31, A61K 31/4164, A61P 5/00
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15155712

Antibody formulations

IPC classification:
A61K 39/395, A61K 9/00, C07K 16/28, C07K 16/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Alastair George Sayce, GlaxoSmithKline
Status:
The patent has been granted
EP12891015

PRESSURE RESPONSIVE DOWNHOLE TOOL HAVING A SELECTIVELY ACTIVATABLE PRESSURE RELIEF VALVE AND RELATED METHODS

IPC classification:
E21B 34/08, E21B 34/06
Applicant:
Halliburton Energy Services, Inc.
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Agent:
Hoffmann Eitle PartmbB
Status:
GRANT OF PATENT INTENDED
EP12734212

NOVEL USES

IPC classification:
A61K 39/395
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Alastair George Sayce, GlaxoSmithKline
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13857873

NOVEL PHARMACEUTICAL COMPOSITION

IPC classification:
A61K 31/519, A61K 9/14, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13858515

COMBINATION

IPC classification:
A61K 9/20, C07D 231/38, A61P 35/00
Applicant:
GlaxoSmithKline LLC
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14730592

COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER

IPC classification:
A61P 35/00, A61K 31/506, A61K 31/4439, A61K 45/06
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14819084

PHARMACEUTICAL DOSAGE FORMS

IPC classification:
A61K 31/506, A61K 9/48, A61K 9/16
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16750495

COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER

IPC classification:
C07K 16/28, C07K 16/24, A61K 39/395
Applicant:
Novartis AG
Agent:
Yixin Pfister-Fu, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature